This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ChemoCentryx Gestion
Gestion contrôle des critères 1/4
Informations clés
Directeur général
n/a
Rémunération totale
Pourcentage du salaire du PDG | n/a |
Durée du mandat du directeur général | no data |
Propriété du PDG | n/a |
Durée moyenne d'occupation des postes de direction | 2.6yrs |
Durée moyenne du mandat des membres du conseil d'administration | pas de données |
Mises à jour récentes de la gestion
Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10PDG
ChemoCentryx n'a pas de PDG, ou nous n'avons pas de données sur eux.
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Senior VP of Finance & Principal Accounting Officer | less than a year | pas de données | pas de données | |
Vice President of Investor Relations & Corporate Communications | no data | pas de données | pas de données | |
Senior Vice President of Human Resources | 2.6yrs | pas de données | pas de données | |
Senior Vice President of Technical Operations | 2.6yrs | pas de données | pas de données |
2.6yrs
Durée moyenne de l'emploi
Gestion expérimentée: CCXI's management team is considered experienced (2.6 years average tenure).